6990.HK
Bayzed does healthcare

Innovative cancer drug company Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. (6990.HK) announced on Thursday it plans to sell 5.92 million shares through a placement, representing 2.54% of its enlarged share capital. It set the placement price at HK$331.8 per share, representing a 7.58% discount from the stock’s previous closing price of HK$359. The offering is expected to raise HK$1.96 billion ($250 million).

The company said it will use proceeds from the sale for R&D, clinical trials, registration filings, manufacturing and drug commercialization, and to replenish its working capital and for general corporate purposes.

Kelun-Biotech develops and sells innovative drugs, targeting conditions such as breast cancer, non-small cell lung cancer, and gastrointestinal cancers. In 2024, the company recorded revenue of 1.93 billion yuan, up 67.8% year-on-year, while its net loss narrowed by 53.5% to 267 million yuan.

Kelun-Biotech’s shares fell in Thursday morning trading, closing down 6.9% at HK$334.20 by the midday break.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

robotaxi commercialization faces hidden barriers

China’s robotaxi commercialization faces hidden barriers

Key hurdles have shifted from purely technological breakthroughs to feasible business models and implementation of policy and regulatory frameworks    By Lead Leo Research Institute In 2025, China’s robotaxi industry…
Illustration of a cosmetic surgeon

Private healthcare’s unclear road, and a surging cosmetic surgeon

Private clinic operators for medical treatments like eye and dental care are facing a difficult path as Chinese consumers rein in their spending. What's ahead for this group? And cosmetic surgery services provider So-Young's shares have soared in recent weeks as investors embrace its shifting business model. Why are they suddenly so confident?